FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293366304> ?p ?o ?g. }

• W4293366304 endingPage "408" @default.
• W4293366304 startingPage "408" @default.
• W4293366304 abstract "We designed this randomised, open-label, parallel group, multi-centre study to investigate the efficacy and safety of glycopyrronium/formoterol, a long-acting muscarinic antagonist/long-acting β2-agonist fixed dose combination, delivered through a dry powder inhaler (DPI) in patients with chronic obstructive pulmonary disease (COPD).We randomised (1:1) patients with moderate to severe COPD (N = 356) to receive glycopyrronium 25 μg/formoterol 12 μg via DPI twice daily (GF-DPI) or glycopyrronium 50 μg monotherapy via DPI once daily (G-DPI). The primary study endpoint was the mean change from the baseline in pre-dose trough-forced expiratory volume in one second (FEV1) at 12 weeks.At week 12, the mean increase from the baseline in pre-dose trough FEV1 was higher in the GF-DPI group (120 ml) than in the G-DPI (60 ml) group. The mean difference (MD) between treatment groups was 0.06 L (95% CI: 0.00-0.12 L, P < 0.0001 for non-inferiority). At week 12, the mean pre-dose forced vital capacity (FVC), 1 hour post-dose FEV1, and post-dose FVC increased significantly from the baseline only in the GF-DPI group (p < 0.0001). The reduction in the COPD assessment test score was greater in the GF-DPI group (p = 0.0379). The average daily number of puffs of rescue medication and the reduction in mean modified Medical Research Council scale, COPD, and Asthma Sleep Impact Scale score at week 12 were similar between groups (p > 0.05). Overall, 35 adverse events and two serious adverse events unrelated to study drugs were reported. Both groups had similar results for overall drug safety.The results demonstrate efficacy and safety of GF-DPI in Indian patients with moderate to severe COPD. Treatment with GF-DPI significantly improved the lung function and quality of life and was well tolerated." @default.
• W4293366304 created "2022-08-28" @default.
• W4293366304 creator A5000000717 @default.
• W4293366304 creator A5002808148 @default.
• W4293366304 creator A5023335182 @default.
• W4293366304 creator A5027721482 @default.
• W4293366304 creator A5054334398 @default.
• W4293366304 creator A5056224026 @default.
• W4293366304 creator A5057002220 @default.
• W4293366304 creator A5059664529 @default.
• W4293366304 creator A5060773281 @default.
• W4293366304 creator A5066263622 @default.
• W4293366304 creator A5070151867 @default.
• W4293366304 creator A5073227636 @default.
• W4293366304 creator A5086534702 @default.
• W4293366304 creator A5087668195 @default.
• W4293366304 creator A5087945409 @default.
• W4293366304 date "2022-01-01" @default.
• W4293366304 modified "2023-10-14" @default.
• W4293366304 title "Efficacy and safety of glycopyrronium/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease: Results from a multi-centre, open-label, randomised study" @default.
• W4293366304 cites W1544338576 @default.
• W4293366304 cites W1950043623 @default.
• W4293366304 cites W2017287154 @default.
• W4293366304 cites W2023554430 @default.
• W4293366304 cites W2030987445 @default.
• W4293366304 cites W2051719749 @default.
• W4293366304 cites W2056040906 @default.
• W4293366304 cites W2079698487 @default.
• W4293366304 cites W2082494913 @default.
• W4293366304 cites W2107829061 @default.
• W4293366304 cites W2142449488 @default.
• W4293366304 cites W2166432084 @default.
• W4293366304 cites W2338478977 @default.
• W4293366304 cites W2558903543 @default.
• W4293366304 cites W2591678263 @default.
• W4293366304 cites W2892705619 @default.
• W4293366304 cites W2920859047 @default.
• W4293366304 cites W2940473654 @default.
• W4293366304 cites W3029251778 @default.
• W4293366304 cites W3033438356 @default.
• W4293366304 cites W3092849554 @default.
• W4293366304 cites W3133577607 @default.
• W4293366304 cites W2953773512 @default.
• W4293366304 doi "https://doi.org/10.4103/lungindia.lungindia_92_22" @default.
• W4293366304 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36629200" @default.
• W4293366304 hasPublicationYear "2022" @default.
• W4293366304 type Work @default.
• W4293366304 citedByCount "0" @default.
• W4293366304 crossrefType "journal-article" @default.
• W4293366304 hasAuthorship W4293366304A5000000717 @default.
• W4293366304 hasAuthorship W4293366304A5002808148 @default.
• W4293366304 hasAuthorship W4293366304A5023335182 @default.
• W4293366304 hasAuthorship W4293366304A5027721482 @default.
• W4293366304 hasAuthorship W4293366304A5054334398 @default.
• W4293366304 hasAuthorship W4293366304A5056224026 @default.
• W4293366304 hasAuthorship W4293366304A5057002220 @default.
• W4293366304 hasAuthorship W4293366304A5059664529 @default.
• W4293366304 hasAuthorship W4293366304A5060773281 @default.
• W4293366304 hasAuthorship W4293366304A5066263622 @default.
• W4293366304 hasAuthorship W4293366304A5070151867 @default.
• W4293366304 hasAuthorship W4293366304A5073227636 @default.
• W4293366304 hasAuthorship W4293366304A5086534702 @default.
• W4293366304 hasAuthorship W4293366304A5087668195 @default.
• W4293366304 hasAuthorship W4293366304A5087945409 @default.
• W4293366304 hasBestOaLocation W42933663041 @default.
• W4293366304 hasConcept C126322002 @default.
• W4293366304 hasConcept C165637977 @default.
• W4293366304 hasConcept C197934379 @default.
• W4293366304 hasConcept C2776042228 @default.
• W4293366304 hasConcept C2776136866 @default.
• W4293366304 hasConcept C2776623344 @default.
• W4293366304 hasConcept C2776780178 @default.
• W4293366304 hasConcept C2777419714 @default.
• W4293366304 hasConcept C2777714996 @default.
• W4293366304 hasConcept C2778884479 @default.
• W4293366304 hasConcept C2779871671 @default.
• W4293366304 hasConcept C2780261241 @default.
• W4293366304 hasConcept C2780667556 @default.
• W4293366304 hasConcept C2781018748 @default.
• W4293366304 hasConcept C2909086917 @default.
• W4293366304 hasConcept C3018587741 @default.
• W4293366304 hasConcept C42219234 @default.
• W4293366304 hasConcept C55520419 @default.
• W4293366304 hasConcept C71924100 @default.
• W4293366304 hasConceptScore W4293366304C126322002 @default.
• W4293366304 hasConceptScore W4293366304C165637977 @default.
• W4293366304 hasConceptScore W4293366304C197934379 @default.
• W4293366304 hasConceptScore W4293366304C2776042228 @default.
• W4293366304 hasConceptScore W4293366304C2776136866 @default.
• W4293366304 hasConceptScore W4293366304C2776623344 @default.
• W4293366304 hasConceptScore W4293366304C2776780178 @default.
• W4293366304 hasConceptScore W4293366304C2777419714 @default.
• W4293366304 hasConceptScore W4293366304C2777714996 @default.
• W4293366304 hasConceptScore W4293366304C2778884479 @default.
• W4293366304 hasConceptScore W4293366304C2779871671 @default.
• W4293366304 hasConceptScore W4293366304C2780261241 @default.
• W4293366304 hasConceptScore W4293366304C2780667556 @default.
• W4293366304 hasConceptScore W4293366304C2781018748 @default.

• next